相关实验视频
Updated: Jun 17, 2025

06:21
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
62
随机双盲安慰剂对照研究,评估长效梅萨拉对随便腹的后感染性刺激性肠综合征的影响
Ashok K Tuteja1,2, Daniel T Leung3, John C Fang2
1George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
Neurogastroenterology and motility
|August 6, 2024
概括
长期作用的梅萨拉有效地减少了感染后刺激性肠综合征 (PI-IBS) 患者的症状,改善了他们的生活质量. 这种抗炎治疗为管理PI-IBS提供了一个有前途的选择,PI-IBS是一种通常与低度肠道炎症相关的疾病.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 后感染性刺激性肠综合征 (PI-IBS) 发生在胃肠炎后,与低度肠炎症有关.
- 之前的研究探讨了抗炎药物梅萨胺,用于IBS症状管理.
- 这项研究专门研究了PI-IBS患者长效梅萨拉的疗效.
研究的目的:
- 评估长效梅萨拉胺在治疗后感染性易怒肠综合征 (PI-IBS) 的有效性.
- 评估梅萨拉对PI-IBS患者关键IBS症状和整体生活质量的影响.
主要方法:
- 一个随机的,安慰剂对照试验,涉及61名患有腹占主导地位的IBS (IBS-D) 患者在胃肠炎后.
- 参与者每天接受2.4克长效梅萨拉或安慰剂,持续8周.
- 结果包括肠道症状得分 (BSS),个人IBS症状以及IBS-生活质量 (IBS-QOL) 问卷结果.
主要成果:
- 梅萨拉胺在降低整体肠道症状评分 (BSS) (科恩d = 0.57,p = 0.042) 方面比安慰剂具有统计学上的显著优势.
- 在梅萨拉治疗后,IBS对日常生活的影响程度 (d = 0.72,p = 0.01) 显著改善.
- 在7个IBS症状指标和8个IBS-QOL子尺度中,发现了梅萨拉明优势的趋势.
结论:
- 长效梅沙胺在缓解PI-IBS患者的IBS症状方面是有效的.
- 此外,该疗法也对患有PI-IBS的个体的生活质量产生了积极影响.
- 梅萨拉胺为管理PI-IBS提供了一个可行的治疗选择.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Constipation-Predominant IBS
149
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
149
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
154
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
154
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124

